Navigation Links
Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
Date:8/7/2008

Diego, California, is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of HIV, gout, cancer and inflammatory diseases. We have four product candidates in clinical trials and others in preclinical development and discovery. Our most advanced product candidate is RDEA806, an NNRTI, which has successfully completed a Phase 2a study for the treatment of patients with HIV. We have evaluated our second-generation NNRTI for the treatment of HIV, RDEA427, in a human micro-dose pharmacokinetic study and have selected it for clinical development. RDEA594, our lead product candidate for the treatment of gout, is in preclinical development. We are currently evaluating our lead MEK inhibitor, RDEA119, in a Phase 1 study in advanced cancer patients and have completed a Phase 1 study in normal healthy volunteers as a precursor to trials in patients with inflammatory diseases. Lastly, we have evaluated our second-generation MEK inhibitor for the treatment of cancer and inflammatory diseases, RDEA436, in a human micro-dose pharmacokinetic study and have selected it for clinical development.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding our goals, including the expected properties and benefits of RDEA806, RDEA427, RDEA594, RDEA119, RDEA436 and our other compounds and the results of preclinical, clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays in comme
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
11. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... and TORONTO ... Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical ... development of improved novel formulations and alternative ... announces expansion of its pharmaceutical development implementing ... direction includes large molecule drugs that will address ...
(Date:7/29/2014)... Mass., July 29, 2014 Cynosure, Inc. ... markets laser- and light-based aesthetic treatment systems for high-volume ... ended June 30, 2014. Second-quarter 2014 financial results incorporate ... on June 24, 2013. Second-Quarter ... increased 45% to $72.6 million , Non-GAAP net ...
(Date:7/29/2014)...  Novation, a VHA and UHC company, today ... features that automate key health care supply chain ... Association.  The new and enhanced ... Value Analysis, Item Master and Formulary – are ... most critical challenges brought on by health care ...
Breaking Medicine Technology:EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 2EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 3EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 4Cynosure Reports Second-Quarter 2014 Financial Results 2Cynosure Reports Second-Quarter 2014 Financial Results 3Cynosure Reports Second-Quarter 2014 Financial Results 4Cynosure Reports Second-Quarter 2014 Financial Results 5Cynosure Reports Second-Quarter 2014 Financial Results 6Cynosure Reports Second-Quarter 2014 Financial Results 7Cynosure Reports Second-Quarter 2014 Financial Results 8Cynosure Reports Second-Quarter 2014 Financial Results 9Cynosure Reports Second-Quarter 2014 Financial Results 10Cynosure Reports Second-Quarter 2014 Financial Results 11Cynosure Reports Second-Quarter 2014 Financial Results 12Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 2Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 3Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 4Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 5
... 2011 PediaVision today announced that Loma Linda ... the State of California to receive the revolutionary ... University,s Department of Ophthalmology is offering free vision ... the support of First 5 Riverside , ...
... small businesses struggle to afford health benefits, a ... Health Benefits regulations could include special interest protections that ... costs, the Pharmaceutical Care Management Association (PCMA) ... for thousands of small businesses throughout America. ...
Cached Medicine Technology:Loma Linda University Expands Vision Screening Program With Revolutionary New Screening Device, Spot 2Loma Linda University Expands Vision Screening Program With Revolutionary New Screening Device, Spot 3Loma Linda University Expands Vision Screening Program With Revolutionary New Screening Device, Spot 4Some Essential Benefits Rules Could Worry Small Businesses 2
(Date:7/29/2014)... Merrick, NY (PRWEB) July 29, 2014 Summer is ... whether that means enjoying a hike, swimming in a pool or ... it’s time for fleas and ticks. The Puppy Store is here ... during the summer months. , It’s almost impossible to completely keep ... can take to minimize the chances of their pets coming into ...
(Date:7/29/2014)... 29, 2014 A team of scientists, ... Ethell, PhD, has developed a blood test for Alzheimer’s ... the development of Alzheimer’s disease interventions, according to an ... a puzzle, and this study represents one of several ... the past couple of years,” Ethell said. , The ...
(Date:7/29/2014)... best way to cure most cases of cancer is ... this approach, however, is that the surgeon may fail ... recurrence. , With a new technique, researchers at the ... help surgeons see the entire tumor in the patient, ... relies on an injectable dye that accumulates in cancerous ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 As testosterone ... U.S. courts, Bernstein Liebhard LLP notes that a new ... men with Type 2 diabetes. The research, which was ... Metabolism on June 30th, involved 88 men who suffered ... to moderate aging male symptoms and erectile dysfunction. Roughly ...
(Date:7/29/2014)... America (GSA) and the National Center for Creative ... Columbia University as the 2014 recipient of the Gene ... This award recognizes and honors the seminal work of ... creativity and aging shifted the conceptual focus from a ... inspired individuals to approach longevity asking what wonders can ...
Breaking Medicine News(10 mins):Health News:Protect Dogs From Fleas and Ticks During the Summer 2Health News:Professor Develops Blood Test for Alzheimer’s Disease Risk 2Health News:Penn team makes cancer glow to improve surgical outcomes 2Health News:Penn team makes cancer glow to improve surgical outcomes 3Health News:As Testosterone Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Questioning Effectiveness of Low Testosterone Therapy in Diabetics 2Health News:As Testosterone Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Questioning Effectiveness of Low Testosterone Therapy in Diabetics 3Health News:As Testosterone Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Questioning Effectiveness of Low Testosterone Therapy in Diabetics 4Health News:Charon to receive 2014 Gene D. Cohen Award 2
... (Nasdaq: NUTR ) today reported results for the ... sales for the fiscal 2009 first quarter were $39.6 million ... 2008. For the first quarter of fiscal 2009, net ... compared to net income of $3.2 million, or $0.28 diluted ...
... MOUNTAIN VIEW, Calif., Jan. 29 Concentric Medical, ... removal in ischemic stroke patients, today announced the ... of the Outreach(TM) Distal Access Catheter for use ... Catheter provides neurointerventionalists additional access and support options ...
... growing list of Ancient Minerals international distributors. , ... ... Inc. announced today that Australian company Rejuve Health Products Pty Ltd. ... of Ancient Minerals topical magnesium products. Located in Buderim, Queensland, the ...
... the National Association of Medicaid Fraud Control Units ... has joined the Whistleblower Action Network through his ... Carson City, Nevada. The Whistleblower Action Network ... citizens, known as "relators," who witness fraud against ...
... France, January 29 , - A New Year ... Excluding the Currency Effect, - Higher Earnings Expected ... ophthalmic optics, today,announced consolidated revenue of EUR3,074.5 million for the year ... Excluding the currency effect, growth for the year was a strong ...
... Researchers from Boston University School of Medicine (BUSM) and ... have found that children born more than three months premature, ... the modified checklist for autism in toddlers (M-CHAT). Children ... for developing autism. These findings appear in the January ...
Cached Medicine News:Health News:Nutraceutical Reports Fiscal 2009 Q1 Results 2Health News:Nutraceutical Reports Fiscal 2009 Q1 Results 3Health News:Nutraceutical Reports Fiscal 2009 Q1 Results 4Health News:Nutraceutical Reports Fiscal 2009 Q1 Results 5Health News:Nutraceutical Reports Fiscal 2009 Q1 Results 6Health News:Nutraceutical Reports Fiscal 2009 Q1 Results 7Health News:Concentric Medical Expands Product Offering in Neuro Access 2Health News:The Healing Power of Ancient Minerals Magnesium Oil Now Available Down Under 2Health News:Nationally Recognized Medicaid Fraud Prosecutor Tim Terry Joins Successful Whistleblower Law Practice, Specializing in "Qui Tam" Citizen Suits Under False Claims Acts 2Health News:Nationally Recognized Medicaid Fraud Prosecutor Tim Terry Joins Successful Whistleblower Law Practice, Specializing in "Qui Tam" Citizen Suits Under False Claims Acts 3Health News:Nationally Recognized Medicaid Fraud Prosecutor Tim Terry Joins Successful Whistleblower Law Practice, Specializing in "Qui Tam" Citizen Suits Under False Claims Acts 4Health News:Essilor : 2008 Revenue 2Health News:Essilor : 2008 Revenue 3Health News:Essilor : 2008 Revenue 4Health News:Essilor : 2008 Revenue 5Health News:Essilor : 2008 Revenue 6Health News:Study finds preemies more likely to score positive 2
... ENDOPATH EZ45 Endoscopic Linear Cutter has application ... surgical procedures for transection, resection, and/or creation ... staple line or tissue buttressing materials such ... reloaded seven times for a total of ...
... Linear Cutters provide a 45mm staple and ... the device suitable for many minimally invasive ... transection, resection, and/or creation of anastomoses in ... ,The LONG45A Endocutter has a shaft ...
ACUCLIP Endoscopic Right-Angle Multiple Clip Applier, 10 mm Shaft Diameter with 20, 8 mm Titanium Clips...
Insert only, Pilling-Weck medium clip size...
Medicine Products: